Literature DB >> 2996345

Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.

L Raij, X C Chiou, R Owens, B Wrigley.   

Abstract

Systemic hypertension does not always reflect concomitant glomerular hypertension. At similar levels of systemic hypertension, glomerular injury occurs only in kidneys that lack protective preglomerular vasoconstriction, which results in glomerular hypertension. indeed, glomerular hypertension and glomerular injury do not develop in rats with spontaneous hypertension that have effective preglomerular vasoconstriction. In the experiments reported herein, the normal adaptive response (afferent arteriolar dilation) to a reduction of one and five-sixths of the renal mass in rats with spontaneous hypertension was examined to ascertain whether that response would expose the remaining nephrons to the injurious effects of high perfusion pressure. In addition, the efficacies of two different antihypertensive regimens were compared. Rats with spontaneous hypertension received either no therapy, or a combination of hydralazine, reserpine, and hydrochlorothiazide, or the angiotensin converting enzyme inhibitor enalapril. Three weeks after ablation of one and five-sixths of the renal mass, blood pressure, glomerular filtration rate, urinary protein excretion, and histologic injury scores for mesangial expansion and glomerulosclerosis were determined. Untreated rats with hypertension had severe glomerulosclerosis and mesangial expansion. Both antihypertensive regimens normalized systemic blood pressure and reduced glomerulosclerosis. However, enalapril was more effective than the combination of hydralazine, reserpine, and hydrochlorothiazide in reducing the exaggerated glomerular filtration rate (0.52 +/- 0.40 versus 0.82 +/- 0.10 ml per minute; p less than 0.05), the injury score for mesangial expansion (79 versus 103; p less than 0.05), and the degree of proteinuria (32 +/- 4 versus 42 +/- 3 mg per 24 hours; p less than 0.05). Persistence of hyperfiltration accompanied by increased mesangial expansion, may lead to progression of glomerular damage despite "adequate" control of systemic hypertension, as observed in rats treated with a combination of hydralazine, reserpine, and hydrochlorothiazide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996345     DOI: 10.1016/0002-9343(85)90078-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

1.  Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.

Authors:  G N Marinides; G C Groggel; A H Cohen; T Cook; R L Baranowski; C Westenfelder; W A Border
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

2.  Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.

Authors:  Sydney R Murphy; Annette J Dahly-Vernon; Kathryn M J Dunn; Chun Cheng Andy Chen; Steven R Ledbetter; Jan M Williams; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

3.  Temporal characterization of the development of renal injury in FHH rats and FHH.1BN congenic strains.

Authors:  Jan Michael Williams; Marilyn Burke; Jozef Lazar; Howard J Jacob; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

4.  Effects of enalapril on renal parameters in patients with primary glomerulopathies associated with chronic renal failure.

Authors:  L F Ferder; F Inserra; H Daccordi; L Romano; A Fernández; J Tessler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats.

Authors:  Jan M Williams; Fan Fan; Sydney Murphy; Carlos Schreck; Jozef Lazar; Howard J Jacob; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-21       Impact factor: 3.619

6.  Transcription factor avian erythroblastosis virus E26 oncogen homolog-1 is a novel mediator of renal injury in salt-sensitive hypertension.

Authors:  Wenguang Feng; Phillip Chumley; Minolfa C Prieto; Kayoko Miyada; Dale M Seth; Huma Fatima; Ping Hua; Gabriel Rezonzew; Paul W Sanders; Edgar A Jaimes
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

7.  The pathogenesis and prevention of diabetic nephropathy.

Authors:  R Omachi
Journal:  West J Med       Date:  1986-08

8.  COX-2-derived prostaglandins as mediators of the deleterious effects of nicotine in chronic kidney disease.

Authors:  S Rangarajan; G Rezonzew; P Chumley; H Fatima; M Y Golovko; W Feng; P Hua; E A Jaimes
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-16

Review 9.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 10.  Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Authors:  G S Thind
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.